Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: The preliminary experience in Taiwan

Ming Yang Lee, Tzeon Jye Chiou, Li Yuan Bai, Liang Tsai Hsiao, Giun Yi Hung, Chia Yau Chang, Po Min Chen

研究成果: 雜誌貢獻文章

6 引文 斯高帕斯(Scopus)

摘要

Background. Some studies have proved that intravenous busulfan with cyclophosphamide (used as a component of conditioning regimens for hematopoietic stem cell transplantation) is safer and has fewer complication than oral busulfan in adults, whereas the same proof in pediatric patients is only limited, with no reported data so far from Asian countries. In this study, we aimed to evaluate the efficacy and complications of IV busulfan in pediatric patients. Methods. Three pediatric patients with acute myeloid leukemia were treated by intravenous busulfan combined with cyclophosphamide to compare retrospectively with the treatment with oral busulfan plus intravenous cyclophosphamide in another three pediatric cases having transplantation in the same institute. Results. The results showed that the intravenous busulfan-based regimen had better compliance and less adverse effects including mucositis, hepatic toxicity, transplant-related hepatic veno-occlusive disease, and acute graft-versus-host disease than oral busulfan-based treatment. Conclusions. The conditioning regimen of intravenous busulfan combined with cyclophosphamide is an acceptable alternative for pediatric patients with hematological malignancies in Taiwan. The long-term benefit and adverse effects of intravenous busulfan should be further explored.

原文英語
頁(從 - 到)117-122
頁數6
期刊Journal of the Chinese Medical Association
67
發行號3
出版狀態已發佈 - 三月 1 2004
對外發佈Yes

ASJC Scopus subject areas

  • Medicine(all)

指紋 深入研究「Intravenous busulfan as preparative regimen in pediatric patients receiving hematopoietic stem cell transplantation: The preliminary experience in Taiwan」主題。共同形成了獨特的指紋。

  • 引用此